This study highlights the promising potential of LC–MS as a powerful tool for mAb quality control within the context of upstream processing.

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash ...

Net Income/Loss: Net loss was $34.6 million, or net loss of $0.80 per basic and diluted share for the quarter ended March 31, 2025, as compared to a net loss of $38.2 million, or a net loss of $1.07 ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

NEW YORK, NY, USA I April 26, 2025 I Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational ...

Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) ...

The UK medicines regulator has approved Pfizer’s marstacimab for patients aged 12 years or older with severe haemophilia A or B, offering a new subcutaneous treatment option.

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...

The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application from Aclaris ...

The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies and other drugs be tested on animals, saying in a news release that ...